Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX.

Comparing PAncreatic NeoAdjuvant MAssachusetts and American Joint Committee on Cancer-TNM The AJCC-TNM staging system also had moderate concordance with OS (c-index: 0.60), but the differences between AJCC-stage 0 [mOS: 58.9 months (95% CI: 58.9–nr)] and AJCC-stage I [mOS: 44.9 months (95% CI: 34.2–nr), P = 0.078] and between AJCC-stage II [mOS: 31.6 months (95% CI: 26.0–43.6)] and AJCC-stage III [mOS: 22.2 months (95% CI: 16.2–28.4), P = 0.060] did not reach statistical significance (Supplemental Digital Content Fig. 2, http://links.lww.com/SLA/F397 ).

also in 111,027 other papers